NASDAQ:GDTC CytoMed Therapeutics H1 2026 Earnings Results & Report $0.83 +0.05 (+6.00%) Closing price 03:59 PM EasternExtended Trading$0.82 -0.01 (-1.33%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. CytoMed Therapeutics reported H1 2026 earnings on September 30, 2026. The company reported EPS of $0.05, while revenue was $60.77 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterH1 2026Report DateSeptember 30, 2026TimeBefore Market Opens CytoMed Therapeutics EPS ResultsActual EPS$0.05Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACytoMed Therapeutics Revenue ResultsActual Revenue$60.77 thousandExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile CytoMed Therapeutics H1 2026 Earnings FAQ Did CytoMed Therapeutics beat earnings estimates for H1 2026? CytoMed Therapeutics (NASDAQ:GDTC) reported earnings of $0.05 per share for H1 2026. The report was announced on Wednesday, September 30, 2026. What was CytoMed Therapeutics' revenue for H1 2026? CytoMed Therapeutics reported revenue of $60.77 thousand for H1 2026. CytoMed Therapeutics Earnings HeadlinesCytoMed Chairman Boosts Personal Stake and Funds R&D Expansion at LongevityBankJune 23, 2026 | tipranks.comCytoMed Therapeutics Shareholders Approve All Resolutions at May 22 AGMJune 3, 2026 | tipranks.comPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.November 18 at 1:00 AM | OilPrice (Ad)CytoMed Renames Subsidiary to Drive Asian and International ExpansionMay 11, 2026 | tipranks.comCytoMed Therapeutics Sets May 22, 2026 AGM With Expanded Share-Issuance Mandate on the TableApril 14, 2026 | tipranks.comCytoMed Therapeutics Widens 2025 Loss as It Accelerates Cell Therapy Trials and Southeast Asia ExpansionMarch 31, 2026 | tipranks.comSee More CytoMed Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CytoMed Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CytoMed Therapeutics and other key companies, straight to your email. Email Address About CytoMed TherapeuticsCytoMed Therapeutics (NASDAQ:GDTC) Ltd. is a Singapore-based biotechnology company developing cell-based immunotherapies for cancer. Its research focuses on gamma delta T cells, a type of immune cell, and induced pluripotent stem cell-derived cells for potential use in cancer treatment. The company is developing allogeneic therapies, which are made using cells from donors rather than each patient’s own cells. Its programs are in development, and CytoMed does not have a marketed cancer treatment. Founded in 2018, CytoMed conducts research and development in Singapore and has pursued clinical development activities in the region. Its work is focused on advancing potential therapies through development and testing rather than serving patients through a commercial product portfolio.View CytoMed Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes ShapeGeneral Motors Faces a Cost Squeeze as Factory Automation Takes Center StageNVIDIA's Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?5 Consumer Discretionary Plays Showing Strength During the Tech Sell-OffAMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?Viking’s Low-Water Miss Looks Like a Buy-the-Dip OpportunityDisney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout Upcoming Earnings NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.